{"id":"W4309287965","doi":"10.1080/10428194.2022.2136956","title":"Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Cohort; Internal medicine; Lenalidomide; Oncology; Lymphoma; Refractory (planetary science); Clinical endpoint; Adverse effect; Multiple myeloma; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002168079,0.0007953819,0.0009725902,0.0001797997,0.0002991625,0.0006816935,0.0005752454,0.000776644,0.003473867],"category_scores_gemma":[0.001073631,0.0003245438,0.0009438233,0.0003852013,0.0003279508,0.0006288658,0.000348582,0.001657906,0.0008074409],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007309591,"about_ca_system_score_gemma":0.001124021,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006508289,"about_ca_topic_score_gemma":0.001690567,"domain_scores_codex":[0.9995646,0.0002633351,0.00002102046,0.00005488811,0.00004318645,0.0000530266],"domain_scores_gemma":[0.9995745,0.00006801154,0.0001263985,0.00004495811,0.00003247638,0.0001535861],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.787811,0.02640742,0.0244964,0.002539792,0.003230355,0.0004030048,0.000261994,0.001617889,0.02748812,0.0004944249,0.009739054,0.1155105],"study_design_scores_gemma":[0.8080528,0.1158844,0.06079752,0.0001703637,0.001792862,0.0005273267,0.00006810497,0.0009066593,0.002540887,0.0003780737,0.008849487,0.00003146775],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9805235,0.006941533,0.0007286891,0.0009313092,0.0001280408,0.003322148,0.00410188,0.00008263435,0.003240234],"genre_scores_gemma":[0.9829544,0.003859118,0.001439373,0.001956195,0.0002089491,0.002583274,0.005025133,0.00002257591,0.001950859],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003473867,"threshold_uncertainty_score":0.0116213,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008453224238700503,"score_gpt":0.2541884000132351,"score_spread":0.2457351757745346,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}